ORIGIN 3 Shows Two-Year Kidney-Function Preservation
In the 428-patient final efficacy analysis of Phase III ORIGIN 3, atacicept-vymj preserved estimated glomerular filtration rate versus placebo through two years in adults with primary IgA nephropathy. Mean eGFR change at Week 52…
